BioCardia's CardiAMP CMI Trial Reports 82% Angina Reduction, Durable Exercise Gains
BCDA is trading near its 52-week low of $0.84 (9.7% above the low).
Summary
BioCardia reported strong preliminary results from its CardiAMP Chronic Myocardial Ischemia (CMI) trial at EuroPCR, showing an average 82% reduction in angina episodes and a 179-second increase in exercise tolerance that lasted two years. This positive clinical development is crucial for the company, which is facing severe liquidity issues, a cash runway only until June 2026, and Nasdaq delisting risk, as detailed in recent SEC filings. The robust data for a therapy addressing a significant unmet medical need could be a lifeline, potentially attracting vital funding or partnership interest.
At the time of this announcement, BCDA was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.5M. The 52-week trading range was $0.84 to $2.45. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.